• Longeveron shifted to a more capital-efficient plan centered on licensing partnerships for its stem cell therapy laromestrocel, aiming to rely on partners’ commercial scale and funding to advance development.
• Strategy prioritizes the Phase 2b ELPIS II readout in hypoplastic left heart syndrome, with top-line 12-month data expected in August 2026, to support FDA discussions on a potential path to a biologics license application.
• Planning includes advancing pediatric dilated cardiomyopathy into a single Phase 2 registrational trial in 2027, contingent on financing or a partnership.
• Alzheimer’s disease development is positioned for partnering and non-dilutive funding, based on an FDA-aligned single Phase 2/3 adaptive trial design that could support a future biologics license application.
• Capital plan targets lower cash burn and reduced dilution, supported by a March private placement for up to USD 30 million, with USD 15 million upfront and up to USD 15 million tied to ELPIS II results and share-price conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605201605PRIMZONEFULLFEED9724110) on May 20, 2026, and is solely responsible for the information contained therein.